Biogen | BIIB - Cash And Equivalent

Stock Price
186.20
Daily Change
0.75 0.40%
Monthly
1.96%
Yearly
30.78%
Q1 Forecast
174.35

Biogen reported $3.86B in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.63B 838M Sep/2025
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
ALKERMES USD 616.45M 95.25M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Bayer EUR 5.9B 1.34B Sep/2025
Biogen USD 3.86B 1.1B Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Bristol-Myers Squibb USD 15.73B 3.13B Sep/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Incyte USD 2.93B 508.08M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Moderna USD 1.13B 147M Sep/2025
Neurocrine Biosciences USD 340.2M 76.2M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 672.62M 344.77M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
United Therapeutics USD 1.34B 253M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025